capital · May 16, 2026
Paradox of Biotech Funding in 2026 Shows VCs Ramp Up New Bets While Early-Stage Dwindles
Share the canonical public link.
Biotech VCs ramped up new bets in 2026 while early-stage funding dwindled. In Q1 2026 investors placed about 65 percent of investments into new portfolio companies. Biopharma acquisitions exceeded $31 billion in the same quarter. Vladimir Ivošev posted the analysis on LinkedIn. The report came from bankers at William Blair.
Spend governor blocked model creation: provider_circuit_open (lane=dev, provider=together)